- All eight patients enrolled and dosed in Cohort 1 ahead of previously disclosed guidance of the end of the third quarter of 2026 -

- Independent Safety Monitoring Committee to review Cohort 1 safety and tolerability in accordance with the study protocol -

- Company expects to provide a further update following completion of the Safety Monitoring Committee review –

HUNTSVILLE, Ala., July 23, 2026 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. ("Serina" or the "Company") (NYSE:SER), a clinical-stage biotechnology company developing its proprietary POZ Platform™ drug optimization technology, today announced the completion of enrollment and dosing in Cohort 1 of its ongoing Phase 1b registrational clinical trial evaluating SER-252 in patients with advanced Parkinson’s disease.

All eight patients in Cohort 1 have now been dosed across clinical sites in the United States and Australia. The milestone was achieved ahead of the Company’s previously disclosed guidance to complete Cohort 1 enrollment and dosing by the end of the third quarter of 2026.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.